Oct 2026· International Journal of Advanced Pharmaceutical Sciences and Research· Vol 6, pp. 15-22· 0 citations· 27 references
TL;DR
The scientific and regulatory foundation for pharmacogenomic informed prescribing is developing, but translating it into routine use worldwide remains an unfinished agenda that will require coordinated clinical, informatics, and policy action.
Abstract
The study of individual drug response due to genetic variation, known as Pharmacogenomics (PGx), has transitioned from a research concept to become a key component of precision medicine in the clinic. New advances in genetic research have led to the identification of variants of cytochrome P450 metabolising enzymes (such as CYP2D6, CYP2C19, CYP2C9) and drug transporters (SLCO1B1), and human leukocyte antigen (HLA) genes, which account for much of the inter-individual differences in efficacy and toxicity of commonly used drug classes including antiplatelets, anticoagulants, antidepressants, statins, and chemotherapeutic drugs. This review collates recent literature (2020-2025) on three interwoven themes: (i) clinically actionable genetic variants and guidance for their use in consortia, such as the Clinical Pharmacogenetics Implementation Consortium (CPIC); (ii) the progression of drug response prediction, from rule-based algorithms through regression-based dosing models to novel machine learning and deep learning approaches incorporating multi-omics data; and (iii) the implementation of precision medicine, such as embedding clinical decision support in electronic health records (EHRs), establishing preemptive testing programmes, and the ongoing challenges of ancestral diversity, cost-effectiveness, and workforce education. We include a summary table of representative drug-gene pairs, a methodological comparison table, and an implementation efforts table, along with four figures visualising the PGx prescribing workflow, cytochrome P450 metabolizer phenotypes, an artificial intelligence approach to the prediction pipeline, and global disparities in pharmacogenomic representation. We believe the scientific and regulatory foundation for pharmacogenomic informed prescribing is developing, but translating it into routine use worldwide remains an unfinished agenda that will require coordinated clinical, informatics, and policy action.
Clinical pharmacogenomics (PGx) is an emerging component of precision medicine that examines how inherited genetic variation influences an individual's response to medicines. Genetic differences affecting drug-metabolizing enzymes, transporters, receptors, immune pathways and therapeutic targets can contribute to inter...
Kalyani R· Bulletin of Advanced Drug De...· 0 citations
The molecular and genetic basis of pharmacogenomic variability, clinically relevant biomarkers, enabling technologies, therapeutic applications, implementation pathways, and implications for clinical outcomes will be explored.
Swathi Ratnam Regidi, Surabhi Johari, Sanskar Singh et al.· Genetics and Molecular Resea...· 0 citations
Interindividual variability in drug response remains a critical challenge in contemporary pharmacotherapy, and cytochrome P450 (CYP450) genetic polymorphisms are a principal determinant of this heterogeneity. The CYP450 superfamily mediates the oxidative biotransformation of 70-80% of clinically prescribed medications....
K. Aldossary, Dalia K. Zaafar, Nada A. Alsaleh et al.· Pharmacogenomics (London)· 0 citations
INTRODUCTION
Pharmacogenetics is pivotal in modern HIV management, facilitating the transition from the traditional "one-size-fits-all" model toward personalized precision medicine. By analyzing how unique genetic profiles influence pharmacological responses, clinicians can maximize therapeutic efficacy while minimizin...
Pharmacogenomics (PGx) is a cornerstone of precision medicine, enabling individualized drug therapy by identifying genetic factors that influence drug disposition and response. However, genotype-based predictions frequently fail to reflect actual drug-metabolizing capacity because enzyme activity can be modified by non...
Augusto Garcia-Agundez, José A. G. Agúndez· Frontiers in Genetics· 0 citations
The role of predictive biomarkers and pharmacogenomic profiling in addressing heterogeneity in treatment response, facilitating individualized therapeutic strategies, and improving clinical outcomes is emphasized.
R. Shinde, Janhavi Nimbalkar· INNOSC Theranostics and Phar...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.